
|Videos|May 18, 2017
Long-Term Strategies in Advanced HCC
Long-Term Strategies in Advanced HCC
Advertisement
May 2016
- A 70-year old male with metastatic HCC involving the lung and bone confirmed by biopsy, experiencing mild bone pain
- ECOG=1
- Child-Pugh A
- Therapy was initiated with sorafenib at 400 BID
- Patient experienced grade 1 HTN and grade 1 hand-foot skin reaction, which was managed effectively
April 2017
- Documented radiographic progression
- Therapy with regorafenib at 160mg was initiated
- Patient experienced grade 1 HTN, grade 2 hand-foot skin reaction
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5









































